Department of Clinical Oncology, 102, Pokfulam Road, Queen Mary Hospital, Hong Kong.
Eur J Radiol. 2012 May;81(5):e717-20. doi: 10.1016/j.ejrad.2012.01.035. Epub 2012 Mar 2.
To evaluate the effective dose delivered to patients undergoing sentinel lymph node (SLN) lymphoscintigraphy by taking into account both the transmission dose using the CT component of a SPECT/CT system and the (99m)Tc internal emission dose.
An adult female humanoid phantom and a set of thermoluminescent dosimeters were used in dose measurement from the CT transmission irradiation. The choice of measurement organs in the humanoid was guided by the recommendations described in the International Commission on Radiological Protection report number 103 (ICRP-103). The effective doses due to (99m)Tc internal emission source were re-calculated from measurement data reported in our previous study on the same subject with the use of tissue weighting factors of ICRP-103.
CT transmission dose is the main contribution to the patient total effective dose for both 1-day and 2-day lymphoscintigraphy protocols and for different surgical procedures. Patients undergoing SLN lymphoscintigraphy receive about the same amount of total effective dose of about 3mSv for both 1-day and 2-day protocol, regardless of whether the tissues containing radioactivity would be excised at surgery or not.
Although the total effective dose from using SPECT/CT is equivalent to the annual natural background radiation of about 3mSv, nuclear medicine physicians should be aware of the increase in effective dose for SLN lymphoscintigraphy using hybrid imaging technique of SPECT/CT when compared to conventional planar (57)Co flood source for transmission scan. Results from the current study provide update information in radiation exposure to patients undergoing SLN lymphoscintigraphy with the use of SPECT/CT.
通过考虑 SPECT/CT 系统的 CT 组件的透射剂量和(99m)Tc 内发射剂量,评估接受前哨淋巴结 (SLN) 淋巴闪烁显像术的患者的有效剂量。
使用成人女性人体模型和一组热释光剂量计进行剂量测量,从 CT 透射照射中获得。人体模型中测量器官的选择是根据国际辐射防护委员会报告第 103 号(ICRP-103)中描述的建议进行的。使用 ICRP-103 的组织权重因子,根据我们之前对同一对象进行的相同研究中报告的测量数据,重新计算了(99m)Tc 内发射源引起的有效剂量。
对于 1 天和 2 天的淋巴闪烁显像术方案以及不同的手术程序,CT 透射剂量是患者总有效剂量的主要贡献者。无论放射性物质所在的组织是否在手术中切除,接受 SLN 淋巴闪烁显像术的患者都会接受大约相同的总有效剂量,约为 3mSv。
尽管使用 SPECT/CT 的总有效剂量与约 3mSv 的年自然背景辐射相当,但与传统的平面(57)Co 透射源相比,核医学医师应该意识到使用 SPECT/CT 的混合成像技术进行 SLN 淋巴闪烁显像术会增加有效剂量。当前研究的结果为使用 SPECT/CT 进行 SLN 淋巴闪烁显像术的患者提供了更新的辐射暴露信息。